Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 7/20 | 0.40 |
| ▸ | KDM1A | O60341 | 7/20 | 0.40 |
| ▸ | MAOA | P21397 | 6/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18019719 | 1.00 | SLC6A2 (0.52) | SLC6A2ADRA1ASLC6A3HTR2BSLC18A3 | |
| SCHEMBL4202694 | 1.00 | SLC6A2 (0.52) | SLC6A2ADRA1ASLC6A3HTR2BSLC18A3 | |
| SCHEMBL4202702 | 1.00 | SLC6A2 (0.52) | SLC6A2ADRA1ASLC6A3HTR2BSLC18A3 | |
| SCHEMBL18019718 | 1.00 | SLC6A2 (0.52) | SLC6A2ADRA1ASLC6A3HTR2BSLC18A3 | |
| SCHEMBL4202698 | 1.00 | SLC6A2 (0.52) | SLC6A2ADRA1ASLC6A3HTR2BSLC18A3 | |
| SCHEMBL24477562 | 0.88 | SLC6A2 (0.49) | SLC6A2ADRA1ASLC6A3HTR2BSLC18A3 | |
| SCHEMBL19122811 | 0.88 | SLC6A2 (0.49) | SLC6A2ADRA1ASLC6A3HTR2BSLC18A3 | |
| SCHEMBL9673258 | 0.88 | SLC6A2 (0.49) | SLC6A2ADRA1ASLC6A3HTR2BSLC18A3 | |
| Hydrochloric Acid SCHEMBL23123360 | 0.86 | SLC6A2 (0.47) | SLC6A2ADRA1ASLC6A3HTR2BCHRNB2 | |
| SCHEMBL23173521 | 0.82 | MAPT (0.43) | SLC6A2SLC6A3HTR2BKDM1ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | SLC6A2 4707/4885ADRA1A 778/4885SLC6A3 4617/4885 |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | DGKK, DGKG, DGKA | SLC6A2 4707/4885ADRA1A 778/4885SLC6A3 4617/4885 |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | SLC6A2 4707/4885ADRA1A 778/4885SLC6A3 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.